Efficacy of acupoint injection in the treatment of chronic eczema and its influence on peripheral blood T cells

Hui-Hui Gan,Gao Yang,Ting-Ting Shen
DOI: https://doi.org/10.12998/wjcc.v12.i17.3019
2024-06-16
World Journal of Clinical Cases
Abstract:BACKGROUND Chronic eczema significantly impacts daily life, social interactions, and quality of life; however, no curative treatment has been identified. AIM To determine the clinical efficacy of acupoint injection for chronic eczema and its influence on peripheral blood T cells. METHODS Eighty patients with chronic eczema treated at our hospital between June 2022 and March 2023 were randomly assigned to a control group (n = 40), which received conventional Western medicine treatment, or an observation group (n = 40), which received routine Western medicine treatment plus acupoint injection of triamcinolone acetonide. Response and adverse reaction rates, as well as differences in the levels of serum cytokines IFN-γ, IL-2, IL-4, and IL-10 before and after treatment were investigated. RESULTS No difference in overall response rates were found between the observation and control groups (100% vs 90%, respectively; P > 0.05); however, the observation group had a higher marked response rate than the control group (87.5% vs 52.5%; P < 0.05). Both groups had decreased Eczema Area and Severity Index scores and increased pruritus after treatment (P < 0.05), particularly in the observation group (P 0.05). The observation group exhibited higher post-treatment INF-γ and IL-2 but lower IL-4 levels than the control group (P 0.05). CONCLUSION Acupoint injection of triamcinolone acetonide is safe and effective in treating chronic eczema. Its therapeutic mechanism is related to the regulation of peripheral blood T cell levels, inhibition of inflammatory reactions, and mitigation of immune imbalance.
medicine, general & internal
What problem does this paper attempt to address?